pyrvinium has been researched along with Lung Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Feng, J; Hu, K; Huang, W; Jiang, W; Li, K; Liu, Y; Ma, C; Pang, X; Sun, Z | 1 |
| Atkinson, RL; Debeb, BG; Hang, BI; Klopp, AH; Krishnamurthy, S; Lacerda, L; Lee, E; Li, L; McMurray, JS; Orton, D; Reuben, JM; Solley, TN; Ueno, NT; Woodward, WA; Xu, W | 1 |
| Dong, Q; Han, B; Lou, Y; Sun, J; Wang, H; Zhang, X; Zheng, X | 1 |
3 other study(ies) available for pyrvinium and Lung Neoplasms
| Article | Year |
|---|---|
Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
Topics: A549 Cells; Animals; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Glycolysis; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Proto-Oncogene Proteins p21(ras); Pyrvinium Compounds; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2020 |
The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer.
Topics: Animals; Anthelmintics; Antineoplastic Agents; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Neoplastic Stem Cells; Pyrvinium Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Spheroids, Cellular; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2013 |
Wnt blockers inhibit the proliferation of lung cancer stem cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplastic Stem Cells; Pyrvinium Compounds; Signal Transduction; Tumor Stem Cell Assay; Wnt Proteins; Wnt Signaling Pathway | 2015 |